What We Do       Leadership       Therapeutic Areas       Partnering       News       Contact

moksha8 Brazil announces a strategic alliance with HRA Pharma to commercialize Lysodren as the first step to build an Oncology line in this Market

March 26th, 2018

 

moksha8 Brazil has entered into a Promotion and Distribution Agreement with HRA Pharma to commercialize Lysodren in Brazil as the first step to build an Oncology line in this country. Lysodren (mitotane tablets) is an oral chemotherapeutic agent indicated for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma and until now the only product available in the market for this type of cancer.

 

Adrenocortical carcinoma (ACC) is a rare and aggressive tumor which peaks in incidence during the first and fifth decades of life. ACC has an estimated worldwide annual incidence of 2 cases per million overall. The highest reported annual incidence of pediatric ACC in the world occurs in Southern Brazil (3.4 per million) and is 10-15-fold higher compared to the United States (U.S.), where the annual incidence of pediatric ACC is 0.2-0.3 cases per million*.

 

With this alliance and the new addition to its portfolio, moksha8 expects higher revenue growth and this expansion into the Oncology therapeutic area allows it to achieve a greater presence in the markets in which it operates.

 

The deal is also relevant for moksha8 because with it, the company continues its philosophy to bring innovative treatments to improving the health and quality of life to patients around the world, especially with rare and aggressive disease as adrenal cortical carcinoma.

 

HRA Pharm, a fast growing, innovative healthcare company with headquarters in Paris, France, affirmed that this partnership allows them to expand the international reach of its Endocrinology and Rare Disease Division in different markets such as Europe, United States, Canada, Brazil and South Korea and strengthens its position as a key player in Adrenal Cortical Carcinoma.

 

The companies expect strong results and a possible expansion of the relationship in the South America Country.

 

 

*Adrenocortical Carcinoma in Adults and Children: A Population-Based Outcomes Study involving 1,623 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973-2012)

Remedy Publications LLC   Published 06 May, 2016

 

 

COPYRIGHT © 2006-2019 MOKSHA8 PHARMACEUTICALS, INC. ALL RIGHTS RESERVED. THIS INFORMATION—INCLUDING PRODUCT INFORMATION—IS INTENDED ONLY FOR RESIDENTS OF THE UNITED STATES. THE PRODUCTS DISCUSSED HEREIN MAY HAVE DIFFERENT LABELING IN DIFFERENT COUNTRIES.

 

PRIVACY POLICY | LEGAL DISCLAIMER | LINKEDIN | ENGLISH | PORTUGUESE